Can-Fite BioPharma Spikes On Pancreatic Cancer Inhibition Finding


Praca, Oferty Pracy

Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding

hero image marketbeat 450882

Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israeli biotechnology firm developing small molecule therapeutics for the treatment of cancer, inflammatory diseases and sexual dysfunction. It is aimed at Adenosine A3 receptor (A3AR) and creates a small molecule therapy to bind or adhere to the A3 receptor and interrupt the growth of pathological cells. A3AR was targeted to fight inflammation and cancer over the past 20 years.

Both Namodenoson and Can-Fite’s Piclidenosen are A3AR agonists that induce apoptosis in inflammatory and cancer cells through a molecular mechanism that deregulates Wnt signaling. Big Pharmaceutical companies works on the treatment of liver cancer and other carcinomas, including Eli Lilly & Co. (NYSE: LLY), Bristol-Myers Squibb Co. (NYSE: BMY), and Merck & Co. Inc. (NYSE: MRK).


What are pathological cells?

Pathological cells are abnormal cells that have been altered by a disease. They are identified through blood tests and biopsies and examined under a microscope. Infections, whether viral, fungal or bacterial, can cause cells to become abnormal as normal functions are disrupted. autoimmune diseases cause the immune system to attack its cells.

Degenerative diseases such as Alzheimer’s and Parkinson’s cause cells to lose function and degenerate over time. Cancer cells are a type of pathological cells. They have anomalies that cause them to grow, split and spread out of control. They have distinct structural abnormalities when viewed under a microscope.


Namodenosone (CF102) is an orally bioavailable drug that binds to A3AR with high affinity and selectivity. It is being developed for the treatment of liver cancer and non-alcoholic steatohepatitis (NASH). Namodenosone deregulates the Wnt signaling pathway, a key modulator of cancer cell growth. Irregular activation of the Wnt pathway can lead to uncontrolled cell growth and division, which are hallmarks of cancer cells.


It is currently in Phase 3 of a major trial for the treatment of advanced liver cancer. Namodenosone has been used in a patient with advanced cancer who has been completely cured and free of liver cancer since starting treatment six years ago. Protective effect of Namodenosone on the liver, bone marrow and cardiovascular system

Pancreas cancer

The five-year survival rate for pancreatic cancer is 11%. Can-Fite scientists have discovered a significant anti-cancer effect of Namodenosone in preclinical studies conducted on cells from advanced pancreatic carcinoma patients exposed to Namodenosone. It can be used as monotherapy in combination with standard chemotherapy such as gemcitabine. Namodenosone has a strong safety profile due to its ability to indirectly inhibit pancreatic tumor growth. The company has filed a patent application for the use of Namodenoson in the treatment of pancreatic cancer. The company plans to develop Namodenosone for the treatment of aggressive tumors.

Can-Fite CEO Dr. Pnina “Knowing Namodenosone’s mechanism of action in pancreatic cancer is an important step in moving this indication towards a potential partnership. Our results inform potential dosage and study design and increase the likelihood of success in human trials.”

Can-Fite Dr*g Pipeline

In addition to Namodenosone, two other drugs are in development. Piclidenosene (CF101) is an oral medication for the treatment of autoimmune inflammatory diseases such as psoriasis and rheumatoid arthritis. CF602 is being developed for the treatment of sexual dysfunction. On January 11, 2023, the company had a direct placement of 1 million ADS worth $7.5 million at a price of ADS for the period of $5.50.


med 20230502115431 chart canf

Daily descending triangle

The daily candlestick chart on CANF illustrates the bearish descending triangle that has been forming since peaking at $2.55 on April 3, 2023 as it was sold to the $1.55 swing low range by April 13. The stock has steadily declined from $11.20. The Market Structure Daily Low (MSL) triggered a breakout of the $1.78 level as stocks also attempted to break out of the daily descending triangle range.

The resistance of the falling diagonal trend line of the triangle was at $1.84. The daily 20-period exponential moving average (EMA) is $1.88 and the daily 50-period MA of resistance is $2.23. The daily stochastic is also forming a mini-puppy accelerating higher towards the 40 band. Pullback support levels are found at $1.68, $1.55 swing low, $1.41 and $1.26.


Leave a Reply

Your email address will not be published. Required fields are marked *